7-chloro-6-nitro-2,4(1H,3H)-quinazolinedione | 76822-66-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 7-chloro-6-nitro-2,4(1H,3H)-quinazolinedione
• 英文别名: 7-chloro-6-nitro-1,2,3,4-tetrahydroquinazoline-2,4-dione；7-Chloro-6-nitroquinazoline-2,4(1H,3H)-dione；7-chloro-6-nitro-1H-quinazoline-2,4-dione
• CAS: 76822-66-7
• 化学式: C₈H₄ClN₃O₄
• 分子量: 241.59
• InChiKey: ZOCGHLGJCUHECJ-UHFFFAOYSA-N

物化性质

• 熔点：
  336 °C
• 密度：
  1.664±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  16
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  104
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-chloro-6-nitro-2,4(1H,3H)-quinazolinedione 在 盐酸 、 氨 、 potassium carbonate 、 tin(ll) chloride 作用下， 以 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 33.0h， 生成 6,7-Diamino-1,3-diethylquinazoline-2,4-dione
  参考文献：
  名称：

  Linear expanded xanthines

  摘要：

  DOI：

  10.1007/bf00810080
• 作为产物：
  描述：

  甲基2-胺-4-氯苯酚酯 在 硫酸 、 硝酸 作用下， 反应 1.17h， 生成 7-chloro-6-nitro-2,4(1H,3H)-quinazolinedione
  参考文献：
  名称：

  Synthesis of lin-benzofervenulin, lin-benzotheophylline, and lin-benzocaffeine

  摘要：

  DOI：

  10.1021/jo00321a035

文献信息

• OLIGONUCLEOTIDE
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20150376611A1

  公开（公告）日：2015-12-31

  The present invention provides an oligonucleotide having improved affinity for AGO2, and the like. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like) or formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like} at the 5′ end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3.

  本发明提供了一种具有改善对AGO2亲和力的寡核苷酸等。该寡核苷酸在其5'端具有由式(I)表示的核苷酸残基或核苷酸残基其中X 1 是氧原子或类似物，R 1 是式(IIA)（其中R 5A 是卤素或类似物，而R 6A 是氢原子或类似物）或式(IVA)（其中Y 3A 是氮原子或类似物，而Y 4A 是CH或类似物），或类似物，R 2 是氢原子、羟基、卤素或可选择地取代的较低烷氧基，而R 3 是氢原子或类似物}，并且该核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。
• OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US20170354673A1

  公开（公告）日：2017-12-14

  An oligonucleotide having a nucleotide residue or a nucleoside residue represented by formula (I) wherein X 1 is an oxygen atom or the like, R 1 is formula (IIA) (wherein R 5A is halogen or the like, and R 6A is a hydrogen atom or the like), formula (IVA) (wherein Y 3A is a nitrogen atom or the like, and Y 4A is CH or the like), or the like, R 2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R 3 is a hydrogen atom or the like, or formula (VI) (wherein n2 is 1, 2 or 3)} at the 5′ end thereof, wherein the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3, is provided.

  具有由式(I)表示的核苷酸残基或核苷酸残基的寡核苷酸其中X1是氧原子或类似物，R1是式(IIA)（其中R5A是卤素或类似物，而R6A是氢原子或类似物），式(IVA)（其中Y3A是氮原子或类似物，而Y4A是CH或类似物），或类似物，R2是氢原子，羟基，卤素，或可选择地取代的较低烷氧基，而R3是氢原子或类似物，或式(VI)（其中n2为1、2或3）}在其5'端，其中核苷酸残基或核苷酸残基通过位于位置3的氧原子与相邻核苷酸残基结合。
• Tricyclic dicarbonyl derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05688803A1

  公开（公告）日：1997-11-18

  Compounds of general formula (Ia), (Ib) and (II), wherein R.sup.1 and R.sup.2 each independently signify hydrogen, lower alkyl, lower alkoxy, nitro, trifluoromethyl, amino, halogen, cyano or R.sup.3 R.sup.4 NS(O).sub.2 -- and R.sup.3 and R.sup.4 signify lower alkyl, and R.sup.2 can additionally signify morpholino or thiomorpholino, a 5- or 6-membered heterocycle with 1-3N atoms optionally substituted by lower alkyl, hydroxy, amino or the group --CH.sub.2 NHCH.sub.3, a bicyclic heterocycle with 1-3N atoms or a group --NR.sup.5 R.sup.6 or --OR.sup.5 in which R.sup.5 and R.sup.6 can be the same or different and signify hydrogen, lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, amino-lower alkyl or lower alkylamino-lower alkyl, and X in formula (II) signifies --CH.dbd.CH--, --CH.dbd.N--, --NH--, --CO-- or --O--, as well as pharmaceutically usable salts of compounds of general formula (Ia), (Ib) and (II). They can be used for the treatment or prevention of illnesses, especially for the treatment or prevention of ischemia, hypoglycaemia, hypoxia, cerebral vascular spasms, spasticity, trauma, hemorrhagia, infection (viral, bacterial, amoebic, prional), epileptic seizures, autoimmune diseases, withdrawal symptoms, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, Huntington's disease, intoxications, olivoponto-cerebellar atrophy, spinal cord injuries, schizophrenia, depressions, anxiety states, dependence, pains,autism and mental retardation.

  通式(Ia)、(Ib)和(II)的化合物，其中R.sup.1和R.sup.2分别独立表示氢、较低烷基、较低烷氧基、硝基、三氟甲基、氨基、卤素、氰基或R.sup.3 R.sup.4 NS(O).sub.2 --，而R.sup.3和R.sup.4表示较低烷基，R.sup.2还可以表示吗啡环或硫吗啡环，1-3个N原子的5-或6成员杂环，可选择地由较低烷基、羟基、氨基或基团--CH.sub.2 NHCH.sub.3取代，含有1-3个N原子的双环杂环或--NR.sup.5 R.sup.6或--OR.sup.5基团，其中R.sup.5和R.sup.6可以相同也可以不同，并表示氢、较低烷基、羟基较低烷基、较低烷氧基较低烷基、氨基较低烷基或较低烷基氨基较低烷基，以及通式(II)中的X表示--CH.dbd.CH--、--CH.dbd.N--、--NH--、--CO--或--O--，以及通式(Ia)、(Ib)和(II)的药用盐。它们可用于治疗或预防疾病，特别是用于治疗或预防缺血、低血糖、缺氧、脑血管痉挛、痉挛、创伤、出血、感染（病毒性、细菌性、阿米巴性、朊病毒性）、癫痫发作、自身免疫疾病、戒断症状、阿尔茨海默病、帕金森病、肌萎缩侧索硬化、亨廷顿病、中毒、橄榄桥小脑萎缩、脊髓损伤、精神分裂症、抑郁症、焦虑状态、依赖、疼痛、自闭症和智力障碍。
• Oligonucleotide having non-natural nucleotide at 5′-terminal thereof
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US10342819B2

  公开（公告）日：2019-07-09

  An oligonucleotide having a nucleotide residue or a nucleoside residue represented by formula (I) wherein X1 is an oxygen atom or the like, R1 is formula (IIA) (wherein R5A is halogen or the like, and R6A is a hydrogen atom or the like), formula (IVA) (wherein Y3A is a nitrogen atom or the like, and Y4A is CH or the like), or the like, R2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R3 is a hydrogen atom or the like, or formula (VI) (wherein n2 is 1, 2 or 3)} at the 5′ end thereof, wherein the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3, is provided.

  具有由式(I)代表的核苷酸残基或核苷残基的寡核苷酸其中X1是氧原子或类似物，R1是式(IIA)（其中R5A是卤素或类似物，R6A是氢原子或类似物），式(IVA)（其中Y3A是氮原子或类似物，Y4A是CH或类似物），或类似物、R2是氢原子、羟基、卤素或任选取代的低级烷氧基，R3是氢原子或类似物，或式（VI）（其中n2是1、2或3）}在其5′端，其中核苷酸残基或核苷残基通过位置3的氧原子与相邻的核苷酸残基结合。
• Oligonucleotide
  申请人：Kyowa Hakko Kirin Co., Ltd.

  公开号：US10378011B2

  公开（公告）日：2019-08-13

  An oligonucleotide having improved affinity for AGO2 is disclosed. The oligonucleotide has a nucleotide residue or a nucleoside residue represented by formula (I) wherein X1 is an oxygen atom or the like, R1 is formula (IIA), wherein R5A is halogen or the like, and R6A is a hydrogen atom or the like, or formula (IVA) wherein Y3A is a nitrogen atom or the like, and Y4A is CH or the like, or the like, R2 is a hydrogen atom, hydroxy, halogen, or optionally substituted lower alkoxy, and R3 is a hydrogen atom or the like at the 5′ end thereof, and the nucleotide residue or the nucleoside residue binds to an adjacent nucleotide residue through the oxygen atom at position 3. A method for improving the knockdown activity of an oligonucleotide wherein the oligonucleotide has a knockdown activity against an mRNA encoding a protein involved in a disease.

  本发明公开了一种对 AGO2 具有更好亲和力的寡核苷酸。该寡核苷酸具有由式（I）代表的核苷酸残基或核苷残基，其中 X1 是氧原子或类似物，R1 是式（IIA），其中 R5A 是卤素或类似物，R6A 是氢原子或类似物，或式（IVA），其中 Y3A 是氮原子或类似物、和 Y4A 是 CH 或类似物，或类似物，R2 是氢原子、羟基、卤素或任选取代的低级烷氧基，R3 是其 5′端的氢原子或类似物，核苷酸残基或核苷残基通过位置 3 的氧原子与相邻的核苷酸残基结合。一种提高寡核苷酸敲除活性的方法，其中寡核苷酸对编码涉及疾病的蛋白质的mRNA具有敲除活性。